1. Patients’ findings after COVID-19 infection and vaccinations: what to expect from [18F]FDG PET/CT

   • Martina Sollini
   • Fabrizia Gelardi
   • Arturo Chiti

   Editorial 20 December 2021 Pages: 791 - 795

   

2. Firefly luciferase offers superior performance to AkaLuc for tracking the fate of administered cell therapies

   • Francesco Amadeo
   • Antonius Plagge
   • Arthur Taylor

   Original Article Open access 27 July 2021 Pages: 796 - 808

   

3. Noninvasive assessment of coronary microvascular dysfunction using SPECT myocardial perfusion imaging and myocardial perfusion entropy quantification in a rodent model of type 2 diabetes

   • Adrien Carabelli
   • Marjorie Canu
   • Laurent M. Riou

   Original Article 21 August 2021 Pages: 809 - 820

   

4. Eribulin improves tumor oxygenation demonstrated by ¹⁸F-DiFA hypoxia imaging, leading to radio-sensitization in human cancer xenograft models

   • Tomoki Bo
   • Hironobu Yasui
   • Yuji Kuge

   Original Article 01 September 2021 Pages: 821 - 833

   

5. Two experts and a newbie: [¹⁸F]PARPi vs [¹⁸F]FTT vs [¹⁸F]FPyPARP—a comparison of PARP imaging agents

   • Sophie Stotz
   • Johannes Kinzler
   • Andreas Maurer

   Original Article Open access 06 September 2021 Pages: 834 - 846

   

6. RGD-functionalised melanin nanoparticles for intraoperative photoacoustic imaging-guided breast cancer surgery

   • Jing-Jing Liu
   • Zun Wang
   • Guo-Jun Zhang

   Original Article Open access 10 September 2021 Pages: 847 - 860

   

7. ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer

   • Weiyu Chen
   • Miao Li
   • Weibo Cai

   Original Article 14 September 2021 Pages: 861 - 870

   

8. Fibroblast activation protein targeted therapy using [¹⁷⁷Lu]FAPI-46 compared with [²²⁵Ac]FAPI-46 in a pancreatic cancer model

   • Yuwei Liu
   • Tadashi Watabe
   • Frederik Giesel

   Original Article Open access 18 September 2021 Pages: 871 - 880

   

9. An [18F]FDG-PET/CT deep learning method for fully automated detection of pathological mediastinal lymph nodes in lung cancer patients

   • David Wallis
   • Michaël Soussan
   • Irène Buvat

   Original Article Open access 14 September 2021 Pages: 881 - 888

   

10. Myocardial perfusion SPECT findings in postCOVID period

    • Mine Araz
    • Çiğdem Soydal
    • Elgin Özkan

    Original Article 07 September 2021 Pages: 889 - 894

11. International consensus on the use of tau PET imaging agent ¹⁸F-flortaucipir in Alzheimer’s disease

    • Mei Tian
    • A. Cahid Civelek
    • Molecular Imaging-based Precision Medicine Task Group of A3 (China-Japan-Korea) Foresight Program

    Guidelines Open access 03 January 2022 Pages: 895 - 904

    

12. Peripheral inflammation is associated with brain SPECT perfusion changes in schizophrenia

    • Guillaume Fond
    • Alexandra Garosi
    • Eric Guedj

    Original Article 18 August 2021 Pages: 905 - 912

    

13. Similar patterns of [¹⁸F]-FDG brain PET hypometabolism in paediatric and adult patients with long COVID: a paediatric case series

    • Aurelie Morand
    • Jacques-Yves Campion
    • Eric Guedj

    Original Article 19 August 2021 Pages: 913 - 920

    

14. Decrease in the cortex/striatum metabolic ratio on [¹⁸F]-FDG PET: a biomarker of autoimmune encephalitis

    • Nicolas De Leiris
    • Berangère Ruel
    • Eric Guedj

    Original Article 31 August 2021 Pages: 921 - 931

    

15. ¹⁸F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma

    • Jakoba J. Eertink
    • Tim van de Brug
    • Josée M. Zijlstra

    Original Article Open access 18 August 2021 Pages: 932 - 942

    

16. Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements

    • J. J. Eertink
    • A. I. J. Arens
    • the HOVON imaging workgroup

    Original Article Open access 02 September 2021 Pages: 943 - 952

    

17. [¹⁸F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies

    • Dan Cohen
    • Efrat Luttwak
    • Einat Even-Sapir

    Original Article 04 September 2021 Pages: 953 - 962

    

18. The potential utility of [⁶⁸ Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent—comparison with [¹⁸F]FDG

    • Lianjun Lan
    • Hanxiang Liu
    • Lin Qiu

    Original Article 19 August 2021 Pages: 963 - 979

    

19. Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma

    • Shan-Shan Yang
    • Yi-Shan Wu
    • Fang-Yun Xie

    Original Article Open access 01 September 2021 Pages: 980 - 991

    

20. Comparison of nodal staging between CT, MRI, and [¹⁸F]-FDG PET/MRI in patients with newly diagnosed breast cancer

    • Janna Morawitz
    • Nils-Martin Bruckmann
    • Julian Kirchner

    Original Article Open access 03 September 2021 Pages: 992 - 1001

    

21. Investigating ultra-low-dose total-body [18F]-FDG PET/CT in colorectal cancer: initial experience

    • Hui Tan
    • Danjie Cai
    • Hongcheng Shi

    Original Article 30 August 2021 Pages: 1002 - 1011

    

22. Influence of sarcopenia, clinical data, and 2-[¹⁸F] FDG PET/CT in outcome prediction of patients with early-stage adenocarcinoma esophageal cancer

    • Reut Anconina
    • Claudia Ortega
    • Patrick Veit-Haibach

    Original Article 07 September 2021 Pages: 1012 - 1020

    

23. ⁶⁸Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement

    • Mohammadreza Chavoshi
    • Seyed Ali Mirshahvalad
    • Patrick Veit-Haibach

    Review Article 12 November 2021 Pages: 1021 - 1029

    

24. ⁶⁸Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agent

    • Xiaojiang Duan
    • Zhen Cao
    • Xing Yang

    Original Article 28 August 2021 Pages: 1030 - 1040

    

25. Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [¹⁸F]DCFPyL (PSMA) imaging for standardized reporting

    • Kerstin Johnsson
    • Johan Brynolfsson
    • Aseem Anand

    Original Article Open access 31 August 2021 Pages: 1041 - 1051

    

26. Head-to-head comparison of [⁶⁸ Ga]Ga-P16-093 and [⁶⁸ Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients

    • Guochang Wang
    • Haiyan Hong
    • Hank F. Kung

    Original Article 23 September 2021 Pages: 1052 - 1062

    

27. The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)

    • Matteo Bauckneht
    • Sara Elena Rebuzzi
    • Giuseppe Fornarini

    Original Article Open access 06 September 2021 Pages: 1063 - 1074

    

28. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)

    • Fadi Khreish
    • Zaidoon Ghazal
    • Samer Ezziddin

    Original Article Open access 07 September 2021 Pages: 1075 - 1085

    

29. Vasculitis and bursitis on [¹⁸F]FDG-PET/CT following COVID-19 mRNA vaccine: post hoc ergo propter hoc?

    • Jan-Henning Schierz
    • Christine Merkel
    • Farzana Ali

    Image of the Month 08 September 2021 Pages: 1086 - 1087

    

30. High ⁶⁸ Ga-FAPI-46 uptake in a pulmonary necrotizing granuloma in a patient with subcutaneous lipoma

    • Masatoshi Hotta
    • Matthias R. Benz
    • Jeremie Calais

    Image of the Month 21 September 2021 Pages: 1088 - 1089

    

31. 2-[18F]FDG-PET/CT for early response and brain metabolic pattern assessment after CAR-T cell therapy in a diffuse large B cell lymphoma patient with ICANS

    • Andrea Paccagnella
    • Andrea Farolfi
    • Stefano Fanti

    Image of the Month 22 September 2021 Pages: 1090 - 1091